Advertisement

Topics

A SNP-based blood test for predicting breast cancer survival and determining treatment strategies

14:38 EDT 12 Jul 2018 | NIH

Metastasis is a primary cause of patient morbidity and mortality in solid tumors. Although recent advances in genomic technologies have provided major insights into tumor etiology, there is a significant lack of knowledge regarding the factors that contribute to metastasis.

Through studying the metastatic susceptibility of tumors, NCI researchers discovered a select panel of single nucleotide polymorphisms (SNPs) and a method for predicting breast cancer patient’s survival. In this array, SNPs are analyzed from a patient’s genomic DNA (gDNA). The results can be used to predict whether a patient is likely to respond to current breast cancer treatment strategies. This technology can indicate the probability of responding to treatment and can also identify those patients that require alternative, more aggressive therapeutic strategies.

Importantly, this invention has several advantages over the currently-offered gene expression-based breast cancer prognostic tests. Since this array can be completed following routine blood draw, rather than through a tumor biopsy, the samples are more stable, the process is quicker, simpler, less-invasive, and more cost-effective than current methods.

NIH Ref. No.: 
E-082-2015
Advantages: 
  • Since the array processes DNA from blood rather than tissue from a standard biopsy or resection of a primary tumor, it is faster, simpler, more cost-efficient, less-invasive, and more stable because gDNA is more stable than tumor mRNA
Applications: 
  • Identification of patients with higher susceptibility to tumor progression (i.e., metastasis).
  • Prediction of breast cancer survival (less than 10 years, for example) using a new array and methods.
Development Status: 

Pre-clinical (in vivo)

Updated On: 
Jun 18, 2018
Provider Classifications: 
Publications: 
Patent Application: 
62/297,557
Patent Authority: 
US Provisional
Licensing Contacts: 
Lead Inventor: 
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Diagnostics
DTDT Description: 
Diagnostics
Pat Filing Date: 
2016-02-19
Collaboration Sought: 
Yes
Collaboration Opportunity: 

Licensing and research collaboration

E Number Only: 
E-082-2015
Inventor First Name: 
Kent
Howard
Maxwell
Inventor Last Name: 
Hunter
Yang
Lee

Original Article: A SNP-based blood test for predicting breast cancer survival and determining treatment strategies

NEXT ARTICLE

More From BioPortfolio on "A SNP-based blood test for predicting breast cancer survival and determining treatment strategies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...